Odactra, an oral immunotherapy for house dust mite allergies, requires consistent administration over several weeks to months to achieve its full effect. The medication works by gradually desensitizing the individual to house dust mite allergens, reducing the severity of allergic reactions. The timeframe for noticeable improvement varies depending on individual factors, such as the severity of the allergy and adherence to the prescribed regimen.
The potential benefits of allergen immunotherapy include reduced reliance on symptomatic medications, decreased frequency and intensity of allergic reactions, and improved quality of life. Historically, allergy treatments primarily focused on managing symptoms, but immunotherapy addresses the underlying cause of the allergy, providing a more long-term solution. Clinical trials have demonstrated the efficacy of sublingual immunotherapy in mitigating allergic responses over time.
